Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Ophthalmology and Therapy
Published in: Ophthalmology and Therapy 4/2021

Open Access 01-12-2021 | Streptococci | Review

Endophthalmitis: Changes in Presentation, Management and the Role of Early Vitrectomy

Authors: Emily H. Shao, William B. Yates, I.-Van Ho, Andrew A. Chang, Matthew P. Simunovic

Published in: Ophthalmology and Therapy | Issue 4/2021

Login to get access

Abstract

Endophthalmitis is a sight-threatening condition, and its timely and appropriate management is essential in preventing permanent vision loss. Recent changes in clinical practice in endophthalmitis and advances in modern vitreoretinal surgery may limit the applicability of established randomised clinical trial evidence to current management. This review discusses the epidemiology, pathophysiology, changing patient presentation, diagnosis and advances in the management of endophthalmitis, presenting the existing literature on this topic and results from Sydney Eye Hospital.
Literature
1.
Maneschg OA, Volek E, Németh J, Somfai GM, Géhl Z, Szalai I, Resch MD. Spectral domain optical coherence tomography in patients after successful management of postoperative endophthalmitis following cataract surgery by pars plana vitrectomy. BMC Ophthalmol. 2014;2(14):76.
2.
Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: a randomised trial of immediate vitrectomy and of intravenous antibiotics for the treatment of post- operative bacterial endophthalmitis. Arch Ophthalmol. 1995;113(12):1479–96.
3.
Pathengay A, Flynn HW Jr, Isom RF, Miller D. Endophthalmitis outbreaks following cataract surgery: causative organisms, etiologies and visual acuity outcomes. J Cataract Refract Surg. 2012;38(7):1278–82.PubMed
4.
Chiquet, et al. Eubacterial PCR for bacterial detection and indentification in 100 acute post cataract surgery endophthalmitis. Invest Ophthalmol Vis Sci. 2008;49:1971.PubMed
5.
6.
Barry P, Cordoves L, Gardner S. ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery. 2013.
7.
Hsu J, Gerstenblith AT, Garg SJ, Vander JF. Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without post-injection topical antibiotics. Am J Ophthalmol. 2014;157(3):514-518.e1.PubMed
8.
Wolner B, Liebmann JM, Sassani JW, Ritch R, Speaker M, Marmor M. Late bleb-related endophthalmitis after trabeculectomy with adjunctive 5-fluorouracil. Ophthalmology. 1991;98(7):1053–60.PubMed
9.
DeBry PW, Perkins TW, Heatley G, Kaufman P, Brumback LC. Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol. 2002;120(3):297–300.PubMed
10.
Vaziri K, Kishor K, Schwartz SG, Maharaj AS, Moshfeghi DM, Moshfeghi AA, et al. Incidence of bleb-associated endophthalmitis in the United States. Clin Ophthalmol (Auckl, NZ). 2015;9:317.
11.
Jampel HD, Quigley HA, Kerrigan-Baumrind LA, Melia BM, Friedman D, Barron Y. Risk factors for late-onset infection following glaucoma filtration surgery. Arch Ophthalmol. 2001;119(7):1001–8.PubMed
12.
Soltau JB, Rothman RF, Budenz DL, Greenfield DS, Feuer W, Liebmann JM, et al. Risk factors for glaucoma filtering bleb infections. Arch Ophthalmol. 2000;118(3):338–42.PubMed
13.
Mochizuki K, Jikihara S, Ando Y, Hori N, Yamamoto T, Kitazawa Y. Incidence of delayed onset infection after trabeculectomy with adjunctive mitomycin C or 5-fluorouracil treatment. Br J Ophthalmol. 1997;81(10):877–83.PubMedPubMedCentral
14.
Leng T, Miller D, Flynn HW Jr, Jacobs DJ, Gedde SJ. Delayed-onset bleb-associated endophthalmitis (1996–2008): causative organisms and visual acuity outcomes. Retina. 2011;31(2):344–52.PubMed
15.
Wallin O, Al-ahramy AM, Lundström M, Montan P. Endophthalmitis and severe blebitis following trabeculectomy. Epidemiology and risk factors; a single-centre retrospective study. Acta Ophthalmol. 2014;92(5):426–31.PubMed
16.
Ho IV, Fernandez-Sanz G, Levasseur S, Ting E, Liew G, Playfair J, Downie J, Gorbatov M, Hunyor AP, Chang AA. Early pars plana vitrectomy for treatment of acute infective endophthalmitis. Asia Pac J Ophthalmol (Phila). 2019;8(1):3–7.
17.
18.
McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31:654e61.
19.
Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996;122(1):1–17.PubMed
20.
Kuriyan AE, Weiss KD, Flynn HW Jr, et al. Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes. Am J Ophthalmol. 2014;157:774–80.PubMedPubMedCentral
21.
Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six year experience at a university referral center. Retina. 2011;31:662–8.PubMed
22.
Miller JM, Scott IU, Flynn HW Jr, Smiddy WE, Corey RP, Miller D. Endophthalmitis caused by Streptococcus pneumoniae. Am J Ophthalmol. 2004;138:231–6.PubMed
23.
Ong AP, Angbue Te N, Zagora SL, Symes RJ, Yates W, Chang AA, McCluskey PJ, Simunovic MP. Post-surgical versus post-intravitreal injection endophthalmitis: changing patterns in causative flora. Clin Exp Ophthalmol. 2019;47(1):57–62.PubMed
24.
Aaberg TM Jr, Flynn HW Jr, Schiffman J, et al. Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. Ophthalmology. 1998;105:1004e10.
25.
Eifrig CW, Flynn HW Jr, Scott IU, et al. Acute-onset postoperative endophthalmitis: review of incidence and visual outcomes. Ophthalmic Surg Lasers. 2002;33:373e8.
26.
Wykoff CC, Parrott MB, Flynn HW Jr, et al. Nosocomial acute-onset postoperative endophthalmitis at a university teaching hospital. Am J Ophthalmol. 2010;150:392e8.e2.
27.
Gordon DF, Jong BB. Indigenous flora from human saliva. Appl Microbiol. 1968;16:428e9.
28.
29.
Levison AL, Mendes TS, Bhisitkul R. Post procedural endophthalmitis: a review. Expert Rev Ophthalmol. 2013;8(1):45–62.
30.
Almeida DR, Miller D, Alfonso EC. Anterior chamber and vitreous concordance in endophthalmitis: implications for prophylaxis. Arch Ophthalmol. 2010;128(9):1136–9.PubMed
31.
Al-Turki TA, Al-Shahwan S, Al-Mezaine HS, Kangave D, Abu El-Asrar AM. Microbiology and visual outcome of bleb-associated endophthalmitis. Ocul Immunol Inflamm. 2010;18(2):121–6.PubMed
32.
Katz LJ, Cantor LB, Spaeth GL. Complications of surgery in glaucoma. Early and late bacterial endophthalmitis following glaucoma filtering surgery. Ophthalmology. 1985;92:959–63.PubMed
33.
Almeida DR, Chin EK, Shah SS, Bakall B, Gehrs KM, Boldt HC, Russell SR, Folk JC, Mahajan VB. Comparison of microbiology and visual outcomes of patients undergoing small-gauge and 20-gauge vitrectomy for endophthalmitis. Clin Ophthalmol. 2016;10:167–72.PubMedPubMedCentral
34.
Brod RD, Flynn HW Jr. Endophthalmitis: current approaches to diagnosis and therapy. Curr Opin Infect Dis. 1993;6:628–37.
35.
Margo CE, Mames RN, Guy JR. Endogenous Klebsiella endophthalmitis. Report of two cases and review of the literature. Ophthalmology. 1994;101:1298–301.PubMed
36.
Tseng CY, Liu PY, Shi ZY, Lau YJ, Hu BS, Shyr JM, et al. Endogenous endophthalmitis due to Escherichia coli: case report and review. Clin Infect Dis. 1996;22:1107–8.PubMed
37.
ESCRS Guidelines on prevention, investigation and management of postoperative endophthalmitis. In: Peter Barry, Wolfgang Behrens-Baumann, Uwe Pleyer & David Seal, editors. The European Society for Cataract & Refractive Surgeons, Version 2 August 2007.
38.
Group EES. Prophylaxis of postoperative endophthalmitis following cataract surgery: 740 Adv Ther (2016) 33:727–746 results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33(6):978–88.
39.
Kazi AA, Jermak CM, Peyman GA, Aydin E, Riazi-Esfahani M. Intravitreal toxicity of levofloxacin and gatifloxacin. Ophthalmic Surg Lasers Imaging Retina. 2006;37:224–9.
40.
Aydin E, Kazi AA, Peyman GA, Esfahani MR. Intravitreal toxicity of moxifloxacin. Retina. 2006;26:187–90.PubMed
41.
Gao H, Pennesi ME, Qiao X, et al. Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models. Invest Ophthalmol Vis Sci. 2006;47:1606–11.PubMed
42.
Sharma YR, Gaur N, Chandra P, Takkar B. Predictors of visual outcomes and microbial profile in endophthalmitis. Ophthalmic Surg Lasers Imaging Retina. 2016;47(11):991–8.PubMed
43.
Oum BS, D’Amico DJ, Wong KW. Intravitreal antibiotic therapy with vancomycin and aminoglycoside. An experimental study of combination and repetitive injections. Arch Ophthalmol. 1989;107(7):1055–60.PubMed
44.
Gan, et al. Intravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis. BJO. 2001;85:1289.
45.
Gan IM, Ugahary LC, van Dissel JT, et al. Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomised trial. Graefes Arch Clin Exp Ophthalmol. 2005;243:1200–5.PubMed
46.
Das T, Jalali S, Gothwal VK, Sharma S, Naduvilath TJ. Intravitreal dexamethasone in exogenous bacterial endophthalmitis: results of a prospective randomised study. Br J Ophthalmol. 1999;83:1050–5.PubMedPubMedCentral
47.
Hall EF, Scott GR, Musch DC, Zacks DN. Adjunctive intravitreal dexamethasone in the treatment of acute endophthalmitis following cataract surgery. Clin Ophthalmol. 2008;2:139–45.PubMedPubMedCentral
48.
Shah GK, Stein JD, Sharma S, et al. Visual outcomes following the use of intravitreal steroids in the treatment of postoperative endophthalmitis. Ophthalmology. 2000;107:486–9.PubMed
49.
Moisseiev E, Abbassi S, Park SS. Intravitreal dexamethasone in the management of acute endophthalmitis: a comparative retrospective study. Eur J Ophthalmol. 2017;27(1):67–73.PubMed
50.
El-Massry A, Meredith TA, Aguilar HE, et al. Aminoglycoside levels in the rabbit vitreous cavity after intravenous administration. Am J Ophthalmol. 1996;122:684–9.PubMed
51.
Aguilar HE, Meredith TA, Shaarawy A, et al. Vitreous cavity penetration of ceftazidime after intravenous administration. Retina. 1995;15:154–9.PubMed
52.
Hariprasad SM, Shah GK, Mieler WF, et al. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Arch Ophthalmol. 2006;124(2):178–82.PubMed
53.
Fuller JJ, Lott MN, Henson NM, et al. Vitreal penetration of oral and topical moxifloxacin in humans. Am J Ophthalmol. 2007;143(2):338–40.PubMed
54.
Lott MN, Fuller JJ, Hancock HA, et al. Vitreal penetration of oral moxifloxacin in humans. Retina. 2008;28(3):473–6.PubMed
55.
Hooper CY, Lightman SL, Pacheco P, Tam PM, Khan A, Taylor SR. Adjunctive antibiotics in the treatment of acute bacterial endophthalmitis following cataract surgery. Acta Ophthalmol. 2012;90(7):e572–3.PubMed
56.
57.
Misra, et al. 23 Gauge sutureless vitrectomy and 20-gauge vitrectomy: a case series comparison. Eye (Lond). 2009;23(5):1187–91.
58.
Tarantola RM, Graff JM, Somani R, et al. Temporal approach for small gauge pars plana vitrectomy combined with anterior segment surgery. Retina. 2012;32(8):1614–23.PubMed
59.
Mahajan VB, Tarantola RM, Graff JM, et al. Sutureless triplanar sclerotomy for 23-gauge vitrectomy. Arch Opthalmol. 2011;129(5):585–90.
60.
Sallam A, Tayler SRJ, Khan A, et al. Factors determining visual outcome in endogenous Candida endophthalmitis. Retina. 2012;32:1129–34.PubMed
61.
Fliney GD, et al. Trends in treatment strategies for suspected bacterial endophthalmitis. Graefes Arch Clin Exp Ophthalmol. 2018;256:833–8.PubMed
62.
Kuhn F, Gini G. Ten years after … are findings of the Endophthalmitis vitrectomy study still relevant today? Graefe’s Arch Clin Exp Ophthalmol. 2005;243(12):1197–9.
63.
Birnbaum FA, Gupta G. The role of early vitrectomy in the treatment of fungal endogenous endophthalmitis. Retin Cases Brief Rep. 2016;10(3):232–5.PubMed
64.
Sridhar, et al. Microbiologic spectrum and visual outcomes of acute-onset endophthalmitis undergoing therapeutic pars plana vitrectomy. Retina. 2017;37(7):1246–51.PubMedPubMedCentral
65.
Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis. 2011;52(5):648–53.PubMed
66.
Binder MI, Chua J, Kaiser PK, et al. Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine. 2003;82:97–105.PubMed
67.
Zhang YQ, Wang WJ. Treatment outcomes after pars plana vitrectomy for endogenous endophthalmitis. Retina. 2005;25:746–50.PubMed
68.
Shen X, Xu G. Vitrectomy for endogenous fungal endophthalmitis. Ocul Immunol Inflamm. 2009;17(148–152):11.
69.
Lingappan A, Wykoff C, Albini T, et al. Endogenous fungal endophthalmitis: causative organisms, management Strategies, and visual acuity outcomes. Am J Ophthalmol. 2012;153:162–6.PubMed
70.
Ozdamar A, Aras C, Ozturk R, Karacorlu M, Ercikan C. In-vitro antimicrobial activity of silicone oil against endophthalmitis causing agents. Retina. 1999;2:122–6.
71.
Bali E, Huyghe P, Caspers L, Libert J. Vitrectomy and silicone oil in the treatment of acute endophthalmitis. Preliminary results. Bull Soc Belge Ophtalmol. 2003;288:9–18.
72.
Arici C, Aras C, Tokman H, Torun M. An in vitro experimental study on the antimicrobial activity of silicone oil against anaerobic bacteria. Ocul Immunol Inflamm. 2016;24(2):173–7.PubMed
73.
Chen X, Adelman RA. Microbial spectrum and resistance patterns in endophthalmitis: a 21-year (1988–2008) review in Northeast United States. J Ocul Pharmacol Ther. 2012;28(4):329–34.PubMed
74.
Lemley CA, Han DP. Endophthalmitis: a review of current evaluation and management. Retina. 2007;27(6):662–80.PubMed
75.
Lalwani GA, Flynn HW Jr, Scott IU, et al. Acute-onset endophthalmitis after clear corneal cataract surgery (1996–2005). Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology. 2008;115(3):473–6.PubMed
76.
Gupta A, Gupta V, Gupta A, et al. spectrum and clinical profile of post cataract surgery endophthalmitis in north India. Indian J Ophthalmol. 2003;51(2):139–45.PubMed
77.
Fan JC, Niederer RL, von Lany H, Polkinghorne PJ. Infectious endophthalmitis: clinical features, management and visual outcomes. Clin Exp Ophthalmol. 2008;36(7):631–6.PubMed
78.
Almeida DRP, Chin EK. Postoperative Infectious Endophthalmitis: Evolving Trends and Techniques. Practices have changed since publication of the EVS in the 1990s. Retina Today. September 2016.
79.
Ness T, Pelz K, Hansen LL. Endogenous endophthalmitis: microorganisms, disposition and prognosis. Acta Ophthalmol Scand. 2007;85:852–6.PubMed
Metadata
Title
Endophthalmitis: Changes in Presentation, Management and the Role of Early Vitrectomy
Authors
Emily H. Shao
William B. Yates
I.-Van Ho
Andrew A. Chang
Matthew P. Simunovic
Publication date
01-12-2021
Publisher
Springer Healthcare
Published in
Ophthalmology and Therapy / Issue 4/2021
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-021-00406-6

Other articles of this Issue 4/2021

Ophthalmology and Therapy 4/2021 Go to the issue

Case Series

Burr-Assisted Peripheral Superficial Keratectomy for the Treatment of Persistent Symptomatic Peripheral Corneal Edema

Review

Ophthalmic Viscosurgical Devices (OVDs) in Challenging Cases: a Review

Original Research

Clinical Outcomes After Second-Generation Trabecular Microbypass Stents (iStent inject®) with Phacoemulsification in Korean Patients

Case Series

Long-Term Observation of Deep Anterior Lamellar Keratoplasty in Patients with Post-LASIK Granular Corneal Dystrophy Type 2: Two Case Reports

Original Research

The Effect of Treatment Discontinuation During the COVID-19 Pandemic on Visual Acuity in Exudative Neovascular Age-Related Macular Degeneration: 1-Year Results

Original Research

Clinical Performance of Samfilcon A Contact Lenses in Intensive Digital Device Users: A Multicenter, Prospective Clinical Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits